Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.

The pharmacogenomics journal - 1 Jun 2016

Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y, Zhu H-J

Abstract excerpt

The aim of the study was to determine the effect of carboxylesterase 1 (CES1) genetic variation on the activation of angiotensin-converting enzyme inhibitor (ACEI) prodrugs. In vitro incubation study of human liver, intestine and kidney s9 fractions demonstrated that the ACEI prodrugs enalapril, ramipril, perindopril, moexipril and fosinopril are selectively activated by CES1 in the liver. The impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Carboxylic Ester Hydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrolysis

Share to Intestines

Share to Kidney

Share to Pharmacogenomic Variants

Share to Prodrugs

Source

Open in PubMed Open full text

Identifiers

PMID: 26076923
DOI: 10.1038/tpj.2015.42
PMCID: PMC6329299

Genes

CES1

Variants

rs71647871

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.PMID 26076923Read ↗

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.Semantic proximity Read ↗

Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.Semantic proximity Read ↗

Pharmacogenetic study of CES1 gene and enalapril efficacy.Semantic proximity Read ↗

CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.Semantic proximity Read ↗

A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.Semantic proximity Read ↗

Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.Semantic proximity Read ↗

Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.Semantic proximity Read ↗

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.Semantic proximity Read ↗

The Influence of Structural Variants of the CES1 Gene on the Pharmacokinetics of Enalapril, Presumably Due to Linkage Disequilibrium with the Intronic rs2244613.Semantic proximity Read ↗

Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.Semantic proximity Read ↗

Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites.Semantic proximity Read ↗

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.